Paper
0
Plasma amyloid beta X‐42/X‐40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease
Authors
Jonathan Vogelgsang,Niels Hansen
Melina Stark,Michael Wagner,Hans‐Wolfgang Klafki,Bárbara Morgado,Anke Jahn‐Brodmann,Björn Schott,Hermann Esselmann,Chris Bauer,Johannes Schuchhardt,Luca Kleineidam,Steffen Wolfsgruber,Oliver Peters,Luisa‐Sophie Schneider,Xiao Wang,Felix Menne,Josef Priller,Eike Spruth,Slawek Altenstein,Andrea Lohse,Anja Schneider,Klaus Fließbach,Ina Vogt,Claudia Bartels,Frank Jessen,Ayda Rostamzadeh,Emrah Düzel,Wenzel Glanz,Enise Incesoy,Michaela Butryn,Katharina Büerger,Daniel Janowitz,Michael Ewers,Robert Perneczky,Boris‐Stephan Rauchmann,Selim Guersel,Stefan Teipel,Ingo Kilimann,Doreen Göerß,Christoph Laske,Marc‐André Weber,Carolin Sanzenbacher,Annika Spottke,Nina Roy‐Kluth,Michael Heneka,Frederic Brosseron,Alfredo Ramierez,Matthias Schmid
+47 authors
,Jens WiltfangJournal
Published
Jun 28, 2024
Show more
Save
Tip0
TipSave
Abstract
Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA) as a test for predicting cognitive decline.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.